Trastuzumab emtanzin in the treatment of HER2-positive metastatic breast cancer in patients with visceral crisis
L.Yu. Vladimirova, I.L. Popova, N.A. Abramova, A.E. Storozhakova, N.M. Tikhanovskaya, K.A. Novoselova, A.A. Lyanova, L.A. Ryadinskaya, M.O. Yezhova, M.A. Teplyakov
Rostov Research Institute of Oncology, Rostov-on-Don, Russia
Background. Metastatic breast cancer (mBC) is an incurable disease; modern treatment approaches, however, allow to achieve clinically significant results.
Methods. Data on the efficacy and safety of trastuzumab emtansine in the second-line therapy in the treatment of 14 patients with mBC with visceral lesions were analyzed.
Results. The overall response to treatment was 71.4% (10 patients), including complete remission in 1 patient, partial remission in 2 (14.3%) patients, stabilization of the process – in 7 (50%), and progression of the process – in 4 (28.6 %) patients. The median of recurrence-free survival was not achieved due to the short follow-up period. Overall recurrence-free survival was 58%, the median overall survival was 9 months. Overall 1-year survival was about 71.4%. The toxic effects of therapy included asthenia, nausea, vomiting, diarrhea, anemia, thrombocytopenia, and leukopenia.
Description of the clinical case. The result of the use of the drug in the first-line treatment of HER2-positive breast cancer in a 62-year-old patient with progression during the adjuvant therapy with trastuzumab is presented.
Conclusion. The drug has a high efficacy for patients with HER-2 positive mBC with a sufficiently favorable toxicity profile.
Keywords: metastatic HER2-positive breast cancer, targeted second-line therapy, trastuzumab emtansine, T-DM1
About the Autors
Corresponding author: Liubov Yu. Vladimirova, MD Professor, Head of the Division of Medicinal Treatment of Tumors, Rostov Research Institute of Oncology, Rostov-on-Don, Russia; e-mail: email@example.com
Address: 63, 14th Line Street, Rostov-on-Don 344037, Russian Federation